[Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
Clofibrate and m-Inositolnicotinate in a daily dosage of 1,5 g Clofibrate and 1,2 g m-Inositolnicotinate during long term treatment effected a good triglyceride fall in all three lipoprotein fractions, especially in VLDL. The changing of the hyperlipoproteinemia phenotypus IV to the phenotypus IIb or IIa under monotherapy with Clofibrate or clofibrinic acid could not be avoided by the combination of Clofibrate with m-Inositolnicotinate. Approximately every fourth hyperlipoproteinemia phenotypus IV or V, treated with a combination therapy, had an increase of beta-Cholesterol in the pathological range of more than 210 mg/dl. The combination of Clofibrate with nicotinic acid is not of greater value than the monotherapy with Clofibrate (Atromid S). A combination of Clofibrate and nicotinic acid is useful when pure nicotinic acid (3 to 4g/daily) or its esters, for example m-Inositol-nicotinate (4 to 6g/daily) or beta-Pyridylcarbinol (800 to 1200 mg/daily) are administered in therapeutic doses. With the increased dosage of nicotinic acid, one must expect a large "drop out" of these appropriate hyperlipoproteinemia patients because of the side-effects resulting from this particular treatment with nicotinic acid.
D004083:Cholestanol / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D009539:Nicotinic Acids / Q000008:administration & dosage*; D009540:Nicotinyl Alcohol / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D002914:Chylomicrons; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D009539:Nicotinic Acids; D014280:Triglycerides; D007294:Inositol; D004083:Cholestanol; D009540:Nicotinyl Alcohol; D002994:Clofibrate
Zur Kombinations- oder Monotherapie der Hyperlipoproteinämien Typ IIb, IV, V mit Clofibrat und m-Inositolnicotinat oder Clofibrinsäure.